Blackstone-Backed Catalent Eyes $699M In Upsized Offering
New Jersey-based drug development and delivery company Catalent Inc. on Tuesday announced pricing of an upsized follow-on offering saying it was looking to raise up to $699.15 million as the company's...To view the full article, register now.
Already a subscriber? Click here to view full article